DEBA PHARMA
ActiveSummary
DEBA PHARMA has been active since 1988 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €6.2m and a net result of €2.1m. Equity is growing by about 12% per year across the filed financial years. Its solvency ranks better than 95% of 92 sector peers (NACE 21, financial year 2025). The computed 12-month bankruptcy probability is below 0.1% (very low).
Articles of association
What the company does
- DurationHow long the company exists; usually unlimited, so until it is dissolved.
- Unlimited
- Name clauseThe name the company operates under according to its articles.
- DEBA PHARMA
- Registered office clauseThe region of the registered office; it decides among other things the language of official documents.
- “Vlaams Gewest” (deed in Dutch)
Who represents it, and how
- Who signsWho may bind the company towards others, for example by signing a contract.
- “Artikel 20: Vertegenwoordiging van de vennootschap Onverminderd de algemene vertegenwoordigingsmacht van de raad van bestuur als college…”
- Board ruleHow the board is made up, meets and takes decisions.
- “3, algemene vergadering” (deed in Dutch)
Capital, shares and profit
- Kind of sharesWhich classes of shares exist and what rights each class carries.
- “Op naam, aandelen” (deed in Dutch)
Meetings and financial year
- Annual meetingWhen the shareholders meet each year, among other things to approve the annual accounts.
- First Saturday of June at 18:00
Oversight and winding up
- Liquidation ruleHow assets are shared after dissolution: creditors first, then shareholders.
- “Behoudens ontbinding en vereffening in één akte, bestuurder(s) in functie aangewezen als vereffenaar(s) indien geen andere vereffenaar…” (deed in Dutch)